Irlandia - angielski - HPRA (Health Products Regulatory Authority)

rowex ltd - escitalopram oxalate - orodispersible tablet - 20 milligram - selective serotonin reuptake inhibitors

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

rowex ltd - escitalopram oxalate - orodispersible tablet - 15 milligram - selective serotonin reuptake inhibitors

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

rowex ltd - escitalopram - film-coated tablet - 20 milligram(s) - selective serotonin reuptake inhibitors; escitalopram

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

rowex ltd - escitalopram - film-coated tablet - 10 milligram(s) - selective serotonin reuptake inhibitors; escitalopram

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

rowex ltd - escitalopram - film-coated tablet - 5 milligram(s) - selective serotonin reuptake inhibitors; escitalopram

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

rowex ltd - escitalopram - film-coated tablet - 15 milligram(s) - selective serotonin reuptake inhibitors; escitalopram

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

3m health care limited - methenamine hippurate - tablets - 1 grams

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

validus pharmaceuticals llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - hiprex is indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of hiprex and other antibacterial drugs, hiprex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. hiprex (methenamine hippurate tablets usp) is contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should not be given to patients taking sulfonamides becau

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

validus pharmaceuticals llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - hiprex is indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of hiprex and other antibacterial drugs, hiprex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. hiprex (methenamine hippurate tablets usp) is contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should not be given to patients taking sulfonamides becau

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

cst pharma ltd - methenamine hippurate - oral tablet - 1gram